Business Wire

New Global Survey Points to Key Issues, Needs and Gaps in Fight to End Smoking

Jaa

The Foundation for a Smoke-Free World released findings today from a global survey to better understand smokers, their experiences, and challenges they face when they try to quit smoking. The survey also highlights their awareness regarding the harm caused by smoking and how their perceptions of cigarettes, alternative products, and nicotine influence their motivation to move away from smoking. The data will shape the development of research to determine the best solutions to accelerate the end of smoking across diverse cultures and economic conditions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180319005647/en/

Figure 1: Which of the following situations, if any, apply to you? (% - Top Three Answers per Countr ...

Figure 1: Which of the following situations, if any, apply to you? (% - Top Three Answers per Country) (Graphic: Business Wire)

The 2018 State of Smoking Survey included 17,421 current smokers, ex-smokers, and non-smokers from 13 countries: Brazil, France, Greece, India, Israel, Japan, Lebanon, Malawi, New Zealand, Russia, South Africa, United Kingdom, United States. In parallel, a series of qualitative focus groups were carried out in seven countries (France, Greece, India, New Zealand, South Africa, United Kingdom, United States) to give additional context to the quantitative results. The survey was conducted by Kantar Public, an integrated consulting and research agency, which was engaged by the Foundation.

The primary findings are:

1. Smoking isn’t an isolated habit. Smokers consider it deeply integrated with their basic pleasures of life, such as eating, drinking, and socializing. Currently implemented cessation methods fail to take these into account, resulting in continued smoking.

2. Smokers know that smoking is harmful to their health, and many consider themselves in poorer health than non-smokers, yet they do not actively engage with their healthcare providers or discuss effective cessation or reduced-harm solutions with them. The healthcare system needs to better engage with smokers, and medical providers need more effective tools to help smokers quit.

3. There is confusion among smokers about the relative harms of smoking and less harmful alternatives. While people “smoke for the nicotine, but die from the tar,” there is still considerable misperception about the risks of nicotine. This impacts their motivation to quit or try reduced risk alternative products.

“I hope this survey will jolt many of the world’s one billion smokers into action to stop smoking, spark a meaningful discussion on the deeply complex reasons so many people continue to smoke, and make clear the urgent need to develop more effective communications and interventions to help smokers quit or substantially reduce their risks,” said Dr. Derek Yach, President of the Foundation for a Smoke-Free World. “By better understanding key drivers behind why people start smoking, barriers to quitting, and motivations to stop, we can help reduce the negative health consequences for many who are trapped in the cycle of addiction to combustible tobacco products.”

Specific findings from the global survey include:

  • Smoking is closely associated with daily rituals and routines like waking up, meal time, coffee/tea breaks, and socializing. In some countries (such as Brazil, Greece, and Lebanon), cigarettes are often smoked with coffee or tea, and in many others, cigarettes are commonly smoked after meals. (See figure 1)
  • In most countries, there was a significant desire to quit smoking. (See figure 2)
  • Most smokers polled recognize that smoking is harmful to their health and self-report as being less healthy than non-smokers, yet they visit their healthcare providers less frequently than non-smokers. (See figures 3 and 4)
  • The main driver that motivates smokers to quit or consider quitting is mainly their concern about their personal health. (See figure 5)
  • Although a large majority of smokers surveyed tried quitting without assistance, those that sought assistance often switched to nicotine-replacement therapy and prescription medicines first. In some countries (i.e., France, Greece, Japan, Lebanon, New Zealand, Russia, UK, US), smokers reported using e-cigarettes and other nicotine replacement devices to cut down or quit smoking cigarettes. (See figure 6)

Further findings from this study are available at: https://www.smokefreeworld.org/sites/default/files/uploads/derek-yach-press-conference-presentation.pdf. High resolution images of the graphics are available at: https://www.dropbox.com/sh/0bw9ckaac0h7cu9/AAB1ihaAu9Ilr_aFdaxZq60ia?dl=0.

“The data demonstrates that by better understanding the unique experiences and struggles of the individual smoker, we can better support each individual’s quit journey,” said Dr. Yach. “In this age of personalized medicine, it is only logical that we should stop treating the world’s smokers as one homogeneous group and start developing and embracing a wide range of solutions that allow individual smokers to select the method that works best for his or her situation and, more importantly, reduce the harm, disease, and death that is caused by smoking.”

About the Foundation for a Smoke-Free World

The Foundation is an independent, private foundation formed and operated free from the control or influence of any third party.  Philip Morris International, S.A. has provided the initial funding to the Foundation.  The Foundation makes grants and supports medical, agricultural and scientific research to end smoking and its health effects, and to address the impact of reduced world-wide demand for tobacco.

Contact information

Feinstein Kean Healthcare
Lynn Blenkhorn, 617-761-6766
Lynn.Blenkhorn@fkhealth.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

AURAK Gains SACSCOC Accreditation15.12.2018 13:49Tiedote

The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/ AURAK delegation during the SACSCOC conference in New Orleans” (Photo: AETOSWire) SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now

Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 20:41Tiedote

Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 20:00Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl

Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 18:42Tiedote

Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00

Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 17:00Tiedote

Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 12:07Tiedote

Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme